Semaglutides are storming the world: this class of drugs not only achieves a reduction in weight of 15 to 20%, but they also appear to protect the heart, liver, and kidneys. Want to know more?
Based on current research, Goldman Sachs estimates the Semaglutides market to reach $100bn by 2030. Join Chris Shibutani, Goldman Sachs Global Investment Research Senior Biotechnology Analyst, for an enlightening session as we explore the next generation GLP1 based anti-obesity/weight management medications. The effect on industries, from pharmaceutical to insurance, medical technologies, food sectors, and airlines, will be disruptive and unpredictable. YPOers will get to explore present facts and future trends with Chris and determine the efficacy of the drugs, the present and future players, and the potential effects on healthcare.
YPOers will leave this event with:
• An understanding of the present impact of these drugs.
• The science behind the drug’s effect on individuals.
• A preview of important innovations in the pipeline.